Dexamethasone inhibits insulin binding to insulin-degrading enzyme and cytosolic insulin-binding protein p82
- PMID: 8573122
- DOI: 10.1006/bbrc.1996.0027
Dexamethasone inhibits insulin binding to insulin-degrading enzyme and cytosolic insulin-binding protein p82
Abstract
We recently demonstrated that insulin specifically binds to several cytosolic insulin-binding proteins (CIBPs) including insulin-degrading enzyme (IDE) and CIBP p82 in cytosol isolated from H35 rat hepatoma cells. Insulin binding to these CIBPs was regulated by culture conditions, such as serum or insulin. In the present study, we examined the effect of dexamethasone on insulin binding to CIBPs in H35 cells. When the cells were treated with 100 nM dexamethasone for 24 hrs, insulin binding to IDE and CIBP p82 was decreased by about 50% without decreasing the expression level of IDE. Insulin added with the dexamethasone prevented the steroid's effect. Furthermore, dexamethasone directly blocked insulin binding to CIBPs in isolated cytosol. These results suggest that dexamethasone, directly or as a complex with other proteins, binds to IDE and CIBP p82 and changes their ability to bind insulin, possibly by inducing a conformational change or by blocking insulin binding sites. IDE was recently identified as a receptor accessory factor for androgen and glucocorticoid receptors and plays an important role in the regulation of gene transcriptional responses. Combined with previous reports, our findings suggest IDE and other CIBPs such as CIBP p82 may play a role in the cross-talk between insulin and the signal transduction pathways of steroid hormones.
Similar articles
-
The expression of and insulin binding to cellular thyroid hormone binding protein, but not insulin degrading enzyme, is increased during 3T3-L1 adipocytes differentiation.Biochem Biophys Res Commun. 1996 May 24;222(3):839-43. doi: 10.1006/bbrc.1996.0831. Biochem Biophys Res Commun. 1996. PMID: 8651932
-
Demonstration of specific insulin binding to cytosolic proteins in H35 hepatoma cells, rat liver and skeletal muscle.Biochem J. 1995 Feb 15;306 ( Pt 1)(Pt 1):21-8. doi: 10.1042/bj3060021. Biochem J. 1995. PMID: 7864812 Free PMC article.
-
Mechanisms of nuclear translocation of insulin.Cell Biochem Biophys. 1999;31(3):307-19. doi: 10.1007/BF02738245. Cell Biochem Biophys. 1999. PMID: 10736753 Review.
-
Insulin acts intracellularly on proteasomes through insulin-degrading enzyme.Biochem Biophys Res Commun. 1998 Mar 17;244(2):390-4. doi: 10.1006/bbrc.1998.8276. Biochem Biophys Res Commun. 1998. PMID: 9514933
-
Insulin-degrading enzyme.Clin Invest Med. 1996 Jun;19(3):149-60. Clin Invest Med. 1996. PMID: 8724818 Review.
Cited by
-
Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.Biomedicines. 2021 Jan 17;9(1):86. doi: 10.3390/biomedicines9010086. Biomedicines. 2021. PMID: 33477364 Free PMC article. Review.
-
Secretagogin Regulates Insulin Signaling by Direct Insulin Binding.iScience. 2019 Nov 22;21:736-753. doi: 10.1016/j.isci.2019.10.066. Epub 2019 Nov 2. iScience. 2019. PMID: 31734536 Free PMC article.
-
Vulnerability and resilience to Alzheimer's disease: early life conditions modulate neuropathology and determine cognitive reserve.Alzheimers Res Ther. 2018 Sep 19;10(1):95. doi: 10.1186/s13195-018-0422-7. Alzheimers Res Ther. 2018. PMID: 30227888 Free PMC article. Review.
-
Positive and negative early life experiences differentially modulate long term survival and amyloid protein levels in a mouse model of Alzheimer's disease.Oncotarget. 2016 Jun 28;7(26):39118-39135. doi: 10.18632/oncotarget.9776. Oncotarget. 2016. PMID: 27259247 Free PMC article.
-
Insulin-Degrading Enzyme: Paradoxes and Possibilities.Cells. 2021 Sep 16;10(9):2445. doi: 10.3390/cells10092445. Cells. 2021. PMID: 34572094 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical